Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,781,329
  • Shares Outstanding, K 146,540
  • Annual Sales, $ 151,860 K
  • Annual Income, $ -80,330 K
  • 60-Month Beta 1.89
  • Price/Sales 18.06
  • Price/Cash Flow N/A
  • Price/Book 11.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.15
  • Number of Estimates 3
  • High Estimate -0.13
  • Low Estimate -0.17
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -1,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.85 +6.33%
on 11/14/19
19.73 -3.80%
on 11/25/19
+1.31 (+7.41%)
since 11/13/19
3-Month
14.61 +29.91%
on 11/04/19
19.73 -3.80%
on 11/25/19
+2.70 (+16.58%)
since 09/13/19
52-Week
13.24 +43.35%
on 12/24/18
19.73 -3.80%
on 11/25/19
+3.73 (+24.46%)
since 12/13/18

Most Recent Stories

More News
Why Is Halozyme Therapeutics (HALO) Up 6.1% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HALO : 18.98 (+1.39%)
Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, will be presented today at the 2019...

HALO : 18.98 (+1.39%)
SmarTrend Watching for Potential Rebound in Shares of Halozyme Therape After 2.24% Loss

Halozyme Therape (NASDAQ:HALO) traded in a range yesterday that spanned from a low of $18.93 to a high of $19.45. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of...

HALO : 18.98 (+1.39%)
Watch for Halozyme Therape to Potentially Pullback After Gaining 1.51% Yesterday

Halozyme Therape (NASDAQ:HALO) traded in a range yesterday that spanned from a low of $19.00 to a high of $19.52. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high...

HALO : 18.98 (+1.39%)
Halozyme Therape Set to Possibly Pullback After Yesterday's Rally of 4.30%

Halozyme Therape (NASDAQ:HALO) traded in a range yesterday that spanned from a low of $17.86 to a high of $18.74. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high...

HALO : 18.98 (+1.39%)
Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session

Halozyme Therapeutics (HALO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ANIK : 53.15 (-0.65%)
HALO : 18.98 (+1.39%)
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of $400.0 million aggregate principal...

HALO : 18.98 (+1.39%)
Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3

Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.

JNJ : 141.38 (+0.03%)
RHHBY : 38.1600 (-0.73%)
HALO : 18.98 (+1.39%)
TAK : 20.23 (-0.44%)
Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -41.67% and -21.40%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

HALO : 18.98 (+1.39%)
Halozyme Therapeutics: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported a loss of $25 million in its third quarter.

HALO : 18.98 (+1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade HALO with:

Business Summary

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected...

See More

Key Turning Points

2nd Resistance Point 19.43
1st Resistance Point 19.21
Last Price 18.98
1st Support Level 18.62
2nd Support Level 18.25

See More

52-Week High 19.73
Last Price 18.98
Fibonacci 61.8% 17.25
Fibonacci 50% 16.49
Fibonacci 38.2% 15.72
52-Week Low 13.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar